Qingyuan Wang

Budget Impact Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) for Preventing Recurrent Clostridioides difficile Infection in the US

A. Guo, T. Lodise, M. Bochan, 2023, Advances in Therapy.

Cost-Effectiveness Analysis of REBYOTA™ (Fecal Microbiota, Live-jslm [FMBL]) Versus Standard of Care for the Prevention of Recurrent Clostridioides difficile Infection in the USA

A. Guo, T. Lodise, M. Bochan, 2023, Advances in Therapy.